BackGinkgo Bioworks Holdings Overview

Ginkgo Bioworks Holdings Intangible Assets

Track Ginkgo Bioworks Holdings's intangible assets ($49M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$48.86M
28.94% YoYΔ $-19.90M vs prior year quarter

Peer average

Loading

Ginkgo Bioworks Holdings Intangible Assets History

Loading

Ginkgo Bioworks Holdings vs. peers: Intangible Assets Comparison

Loading

Ginkgo Bioworks Holdings Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ginkgo Bioworks Holdings (DNA) FAQ

Ginkgo Bioworks Holdings (DNA) currently reports a intangible assets of $49M as of March 2026. That compares with $69M in the prior-year period — down 28.9% year over year. Use the charts on this page to explore Ginkgo Bioworks Holdings's intangible assets history and peer comparisons.

Ginkgo Bioworks Holdings's intangible assets decreased from $69M to $49M — a 28.9% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ginkgo Bioworks Holdings reported $49M in intangible assets as of March 2026. That compares with $69M in the prior-year period — down 28.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $49M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ginkgo Bioworks Holdings, and consider following DNA for alerts when major investors trade the stock.

Ginkgo Bioworks Holdings is classified in the Healthcare sector. On intangible assets, it currently shows $49M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNA with unrelated industries.